United States: Federal Circuit Reiterates That Nucleotide Sequences Are Not Patent Eligible Under 35 U.S.C. § 101

Last Updated: January 2 2019
Article by Matthew E. Barnet

On October 9, 2018, in Roche Molecular Systems, Inc. v. Cepheid, No. 17-1690 (Fed. Cir. 2018), the Federal Circuit upheld a district court decision that claims reciting nucleotide primers in U.S. Patent No. 5,643,723 (the '723 patent) were invalid under 35 U.S.C. § 101.

The '723 patent (assigned to Roche) relates to methods for detecting the pathogenic bacterium M. tubercu­losis, a major cause of tuberculosis. Prior to the '723 patent, standard treatment for M. tuberculosis infec­tion included antibiotics, specifi­cally rifampin. Certain strains of M. tuberculosis, however, were resistant to rifampin, requiring an alternative therapy. It was difficult to rapidly detect rifampin-resistant strains of M. tuberculosis, and a faster diagnos­tic test was desired.

The methods of the '723 patent allow for the rapid detection of M. tuberculosis, including rifampin-resistant strains. Rifampin acts on the rpoB gene, which encodes the β subunit of bacterial RNA poly­merase. The inventors of the '723 patent discovered that the rpoB gene in M. tuberculosis contained eleven "position-specific 'signature nucleo­tides'" that are present in M. tubercu­losis but not in other bacteria.

Based on these eleven M. tuberculo­sis-specific signature nucleotides, the inventors of the '723 patent devel­oped a diagnostic test (i) to identify whether a biological sample contains M. tuberculosis, and (ii) to predict whether the M. tuberculosis, if pres­ent, is resistant to rifampin. The diag­nostic test involved subjecting DNA from the biological sample to ampli­fication by polymerase chain reac­tion (PCR), using nucleotide primers that could hybridize to at least one of the eleven position-specific signature locations in the M. tuberculosis rpoB gene.

Such primers are recited in claim 17 of the '723 patent, as follows:

Claim 17: A primer having 14-50 nucleotides that hybrid­izes under hybridizing condi­tions to an M. tuberculosis rpoB gene at a site comprising at least one position-specific M. tuber­culosis signature nucleotide selected, with reference to FIG. 3 (SEQ ID NO: 1), from the group consisting of:

a G at nucleotide position 2312,

a T at nucleotide position 2313,

an A at nucleotide position 2373,

a G at nucleotide position 2374,

an A at nucleotide position 2378,

a G at nucleotide position 2408,

a T at nucleotide position 2409,

an A at nucleotide position 2426,

a G at nucleotide position 2441,

an A at nucleotide position 2456, and

a T at nucleotide position 2465.

Roche brought a patent infringe­ment case against Cepheid, alleging that Cepheid's commercial assay for detecting M. tuberculosis infringed the '723 patent. Cepheid filed a motion for summary judgment, arguing that the asserted claims were invalid under 35 U.S.C. § 101 as directed to patent-ineligible subject matter. The district court granted Cepheid's motion.

In particular, the district court found that the primer claims of the '723 patent, "which have genetic sequences identical to those found in nature, are indistinguishable from those held to be directed to nonpat­entable subject matter," and thus were invalid.

The Federal Circuit panel reviewed the question of whether the claims were invalid under 35 U.S.C. § 101 de novo.

The panel relied heavily on prec­edent from In re BRCA1- & BRCA2- Based Hereditary Cancer Test Patent Litig., 774 F.3d 755 (Fed. Cir. 2014) (BRCA1) and Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013) (Myriad). In par­ticular, the panel held that "BRCA1 forecloses Roche's arguments" that the claimed primers differed from naturally occurring bacterial DNA by virtue of the 3-prime hydroxyl group on the primers. Slip op. at 10. The panel noted the holding from BRCA1 that the primers in that case were "not distinguishable from the isolated DNA found patent-ineli­gible in Myriad" and thus were not patent-eligible. Id. (citing BRCA1 at 760). The panel further noted that in BRCA1, the court found that "[p] rimers necessarily contain the iden­tical sequence of the [nucleotide] sequence directly opposite to the [DNA] strand to which they are designed to bind. They are structur­ally identical to the ends of DNA strands found in nature." Id. at 10-11 (citing BRCA1 at 760).

Based on this, the panel affirmed the district court decision that the primer claims of the '723 patent were invalid under 35 U.S.C. § 101.

The panel acknowledged that "Roche's discovery of these signa­ture nucleotides on the [M. tubercu­losis] rpoB gene and the designing of corresponding primers are valuable contributions to science and medi­cine, allowing for faster detection of [M. tuberculosis] in a biological sam­ple and testing for rifampin resis­tance." Slip op. at 13-14. The panel, however, stated that "[t]he primers are not patent-eligible because they can be found in nature, not because they are not valuable scientific dis­coveries." Slip op. at 14.

Judge O'Malley filed a concur­ring opinion. In it, she agreed that BRCA1 "compels the conclusion that the primer...claims of [the '723 patent] are not eligible for patent pro­tection." Slip op. at 1. She expressed concern, however, about the BRCA1 holding.

In particular, Judge O'Malley acknowledged the finding of BRCA1 that primers have identical sequences to the natural DNA strands directly opposite the strands to which they bind. She noted, however, that "a finding that the two have identi­cal sequences does not entirely resolve the question of whether they are structurally identical because structure is not defined solely by nucleotide sequence." Slip op. at 7.

Judge O'Malley discussed the evi­dence provided by Roche concern­ing structural differences between the claimed primers and naturally occurring DNA. For example, she discussed Roche's explanation of a structural difference relating to the 3-prime hydroxyl group on the primers, which is absent in the natu­rally occurring bacterial DNA. See slip op. at 7-8. She concluded that "although it is undisputed that all the claimed primers here have nucle­otide sequences that are identical to segments of the naturally occurring rpoB gene found in [M. tuberculo­sis], a genuine factual dispute exists as to whether they have a materially different structure than any DNA molecules typically found in nature." Slip op. at 9. Because of this, Judge O'Malley appears to believe that, at the very least, Cepheid's motion for summary judgment should not have been granted.

The decision in Roche reiterates the previous holdings from BRCA1 and Myriad that naturally occurring nucleotide sequences are not pat­ent eligible under 35 U.S.C. § 101. As seen in Roche, emphasizing the structural differences between syn­thetic nucleotide primers and natu­rally occurring DNA may not be sufficient to establish patent eligibil­ity, especially when the nucleotide sequences are identical.

Instead, to overcome the eligibil­ity hurdle of § 101, it appears that other structural differences are required for nucleotide sequences. Footnote 5 of the panel opinion acknowledges that this is an open question ("We do not address the subject matter eligibility of primers that have been altered - e.g., investi­gator-induced mutation(s) such that their nucleotide sequences are not found in nature, or primers which are chemically modified or labeled by investigators such that they can­not be isolated directly from natu­rally occurring DNA." Slip op. at 13). It seems unlikely, however, that such altered nucleotide sequences reasonably could be considered to be 'products of nature' under § 101—especially with a chemical modification, such as an added flu­orophore for a fluorescence in situ hybridization probe.

In view of this, to overcome the eli­gibility hurdle of § 101, practitioners should emphasize structural differ­ences between claimed nucleotide sequences and naturally occurring sequences whenever possible—espe­cially when those differences are not merely the presence of a 3-prime hydroxyl group in the synthetic nucleotide sequence. Absent such differences, it remains an uphill bat­tle to establish patent eligibility for nucleotide sequences.

Originally published in the IP Litigator journal.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions